% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Iacoboni:300220,
      author       = {G. Iacoboni and K. Rejeski and V. Navarro and T. van
                      Meerten and A. Rampotas and A. Á. Martín-López and M.
                      Bastos and A. Benzaquén and J. L. Reguera-Ortega and C.
                      Carpio and C. Roddie and L. López-Corral and J.
                      Delgado-Serrano and M. Landwehr and S. Stock$^*$ and P.
                      Silva de Tena and P. Abrisqueta and J. de Boer and A. Martin
                      Garcia-Sancho and R. Hernani and M. Kwon and M. Subklewe and
                      M. O'Reilly and P. Barba},
      title        = {{S}ite-specific analysis of extranodal involvement in large
                      {B}-cell lymphoma reveals distinct efficacy with chimeric
                      antigen receptor {T}-cell therapy.},
      journal      = {Leukemia},
      volume       = {39},
      number       = {5},
      issn         = {0887-6924},
      address      = {London},
      publisher    = {Springer Nature},
      reportid     = {DKFZ-2025-00682},
      pages        = {1196-1205},
      year         = {2025},
      note         = {2025 May;39(5):1196-1205},
      abstract     = {Over $60\%$ of relapsed/refractory large B-cell lymphoma
                      (R/R LBCL) patients treated with chimeric antigen receptor
                      (CAR) T-cells experience progressive disease. The impact of
                      site-specific extranodal involvement on CAR-T outcomes has
                      not been fully elucidated. This multicenter study included
                      516 R/R LBCL patients infused with CD19-targeted CAR
                      T-cells; 177 $(34\%)$ had only-nodal (N), 66 $(13\%)$
                      only-extranodal (E) and 273 $(53\%)$ nodal and extranodal
                      (NE) disease at time of CAR T-cells. The NE cohort included
                      more patients with a poor performance status and high tumor
                      burden. In the multivariable analysis, the NE group had a
                      shorter progression-free survival (PFS) (HR 1.27 $[95\%CI$
                      0.98-1.64], p = 0.07) and overall survival (HR 1.41
                      $[95\%CI$ 1.05-1.88], p = 0.02) compared to N. Conversely,
                      we did not identify efficacy differences between N and E
                      patients. A higher number of extranodal sites and specific
                      organ involvement (liver, adrenal glands, pancreas), were
                      associated with shorter PFS. Finally, extranodal involvement
                      increased at time of relapse, displaying heterogeneous
                      individual site clearance rates. In conclusion, patients
                      with concomitant nodal and extranodal involvement at time of
                      CAR-T had worse outcomes, but this cohort harbored high-risk
                      baseline characteristics. An increasing number of extranodal
                      sites and certain disease locations were associated with
                      lower CAR-T efficacy.},
      cin          = {MU01},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40169762},
      doi          = {10.1038/s41375-025-02582-x},
      url          = {https://inrepo02.dkfz.de/record/300220},
}